

**Structure elucidation  
of antiplasmodial  
sesquiterpene lactones  
from *Vernonia staehelinoides*  
and *Oncosiphon piluliferum***

by

Pamisha Pillay

Submitted in partial fulfillment of the requirements for the degree

**MASTER OF SCIENCE**

in the Faculty of Natural & Agricultural Sciences

University of Pretoria

Pretoria

Supervisor : Prof R. Vleggaar

December 2005

**Declaration**

I, the undersigned, hereby declare that the work contained in this dissertation is my own original work and that I have not previously, in its entirety or in part, submitted it at any university for a degree.

**Signature:** .....

**Date:** .....

P. Pillay

## SUMMARY

Malaria continues to be a major cause of mortality and morbidity especially in Sub-Saharan Africa. The emergence and spread of drug resistant parasites has highlighted the need for new chemically diverse, effective drugs. Historically, one of the major sources of antimalarial agents and novel template compounds has been higher order plants. The widespread use of medicinal plants for the treatment of malaria in South Africa represents a diverse resource of potential antimalarial drugs.

Two South African plants, *Vernonia staehelinoides* and *Oncosiphon piluliferum*, were identified as potential sources of new antimalarial drugs through a national multidisciplinary-consortium project aimed at scientifically validating South African medicinal plants for the treatment of malaria. The *in vitro* antiplasmodial activity of extracts of these plants warranted further investigation to identify the biologically active components. Bio-assay guided fractionation based on *in vitro* antiplasmodial activity against the D10 *P. falciparum* strain was used to identify the compounds responsible for the observed activity. Compounds were purified using silica gel column chromatography. The structures of the isolated compounds were elucidated using spectroscopic techniques.

Bioassay-guided fractionation of the organic extracts of *V. staehelinoides* leaves identified a pair of structurally-related hirsutinolides with significant *in vitro* antiplasmodial activity. The compounds were found to be cytotoxic at similar concentrations but proved to be interesting scaffolds for potential structure-activity relationship studies.

Three germacranolides and two eudesmanolides were identified through bioassay-guided fractionation of the organic *O. piluliferum* extract. Selected derivatizations were conducted in order to fully characterize the compounds. The absolute configuration of the major active germacranolide was determined using Mosher's method. The effect of the reduction of the  $\alpha$ -methylene group of the major active

germacranolide on antiplasmodial activity and cytotoxicity was also investigated. The 5 compounds and the reduction product were found to possess varying degrees of *in vitro* antiplasmodial activity and cytotoxicity. None was sufficiently active or selective to be a viable drug candidate but the potential for further structure-activity relationship studies exists.

## ACKNOWLEDGEMENTS

I would like to express my gratitude to my supervisor, Prof. R. Vlegaar, for his invaluable supervision and insight throughout the duration of this work. In addition, I wish to thank my CSIR colleagues Dr Vinesh Maharaj, Dr Gerda Fouche and Dr Louis Ackerman for their guidance.

I gratefully acknowledge the Department of Science and Technology for the Innovation fund Grant (Project 31313) and am also grateful to the Innovation Fund Project Administrators and the CSIR for permission to present this work for degree purposes.

Special mention must be made of members of the Antimalarial consortium who personally contributed to this research: Prof Peter Folb (MRC), Dr Niresh Bhagwandhin (MRC), Prof Pete Smith (UCT), Dr Cailean Clarkson (UCT), Dr Neil Crouch (SANBI), Jean Meyer (SANBI) and Dr Kelly Chibale (UCT).

Heartfelt thanks to my family and friends for their love and support. To my brothers, thank you for your inspiration and encouragement. I dedicate this thesis to my mum and dad who have made great sacrifices to ensure we were able to pursue our dreams.



*Om Saraswati Namah*

**ABBREVIATIONS/FORMULAE COMMONLY USED**

SANBI	South African National Biodiversity Institute
MRC	Medical Research Council
CSIR	Council for Scientific and Industrial Research
UCT	University of Cape Town
WHO	World Health Organisation
Ac	acetyl
Acetyl-CoA	acetyl coenzyme A
APAD	3-acetylpyridine adenine dinucleotide
CDCl <sub>3</sub>	deuterated chloroform
C <sub>6</sub> D <sub>6</sub>	deuterated benzene
CHO	Chinese Hamster Ovarian
DMAP	4-(dimethylamino)pyridine
DMAPP	dimethylallyl pyrophosphate
DMF	dimethylformamide
DMSO	dimethyl sulphoxide
FPP	farnesyl pyrophosphate
GGPP	geranylgeranyl pyrophosphate
GAP	glyceraldehyde 3-phosphate
GPP	geranyl pyrophosphate
H <sub>2</sub> O	water
HMG-CoA	3-hydroxy-3-methylglutaryl coenzyme A
HEPES	<i>N</i> -[2-hydroxyethyl]-piperazine- <i>N'</i> -[2-ethanesulphonic acid]
IPP	isopentenyl pyrophosphate
MVA	mevalonic acid
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MeOH	methanol
MTPA	$\alpha$ -methoxy- $\alpha$ -trifluoromethylphenyl acetic acid

NaBH <sub>4</sub>	sodium borohydride
NaHCO <sub>3</sub>	sodium hydrogen carbonate
Na <sub>2</sub> SO <sub>4</sub>	sodium sulphate
NAD	nicotinamide adenine dinucleotide
NADP	nicotinamide adenine dinucleotide phosphate
NADPH	reduced form of nicotinamide adenine dinucleotide phosphate
NBT	nitroblue tetrazolium
Me	methyl
MeOH	methanol
pLDH	parasite lactate dehydrogenase
PES	phenazine ethosulphate
PBS	phosphate buffered saline
PRBC	packed red blood cells
RPMI	Roswell Park Memorial Institute medium
RBC	red blood cells
SH	thiol or sulfanyl
TRIS	tris(hydroxymethyl)aminomethane
A	absorbance
br	broad resonance
COSY	correlated spectroscopy
<i>c</i>	concentration
d	doublet
dd	doublet of doublets
ddd	doublet of doublets of doublets
dddd	doublet of doublets of doublets of doublets
ddq	doublet of doublets of quartets
ddt	doublet of doublets of triplets
DEPT	distortionless enhancement by polarisation transfer
dq	doublet of quartets
dt	doublet of triplets

EI- MS	electron ionization- mass spectrometry
$^1\text{H}$ NMR	proton ( $^1\text{H}$ ) nuclear magnetic resonance spectroscopy
$^{13}\text{C}$ NMR	carbon-13 nuclear magnetic resonance spectroscopy
HR EI-MS	high resolution electron ionization- mass spectrometry
HMBC	heteronuclear multiple bond correlation
HSQC	heteronuclear single quantum correlation
Hz	hertz
J	coupling constant
Lit.	Literature
IC <sub>50</sub>	inhibitory concentration at which 50% inhibition is achieved
NOESY	nuclear Overhauser effect spectroscopy
m	multiplet
mp	melting point
m/z	mass-to-charge-ratio
ppm	parts per million
q	quartet
R <sub>f</sub>	retention factor
s	singlet
t	triplet
RI	resistance index
SI	selectivity index
TLC	thin layer chromatography
cm	centimeters
h	hours
kV	kilovolts
mg	milligrams
mg/L	milligrams per liter
mm	millimeters
mmol	millimoles



ng/ml	nanograms per milliliter
nm	nanometers
$\mu$ M	micromolar
$\mu$ g/ml	micrograms per milliliter
g/L	grams per liter
spp.	species
subsp.	subspecies
<i>et al.</i>	and others
<i>i.e.</i>	that is
<i>viz.</i>	namely

## CONTENTS

<b>SUMMARY</b>	i
<b>ACKNOWLEDGEMENTS</b>	iii
<b>ABBREVIATIONS/FORMULAE COMMONLY USED</b>	vi
<b>CHAPTER 1</b>	
<b>Malaria and antimalarials from plants</b>	
1.1 History of Malaria	1
1.2 Malaria Today	2
1.3 The Malaria Parasite	3
1.4 Malaria Prevention and Control	5
1.5 Malaria Treatment	6
1.6 Resistance to Antimalarial Drugs	10
1.7 Need for New Antimalarials	11
1.8 Traditional Medicine	11
1.9 Medicinal Plants	12
1.10 Drugs from Plants	14
1.11 Antimalarials from Plants	16
1.12 Antimalarial Drug Discovery	18
1.13 Scope of this Study	19

## CHAPTER 2

### Sesquiterpene lactones

2.1.	Secondary Plant Metabolites	21
2.2.	Terpenoids	22
2.3.	Sesquiterpene Lactone Skeleton	25
2.4.	Sesquiterpene Lactone Biosynthesis	26
2.5.	Biological Activities of Sesquiterpene Lactones	27
2.5.1.	Antitumour and Cytotoxic Activity	28
2.5.2.	Antiplasmodial Activity of Sesquiterpene Lactones	29
2.5.3.	Other Pharmacological Activities of Sesquiterpene Lactones	32

## CHAPTER 3

### Antiplasmodial Activity of *Vernonia staeheleinoides*

3.1	<i>Vernonia staeheleinoides</i> Harv.	33
3.2	<i>In vitro</i> Antiplasmodial Activity of <i>V. staeheleinoides</i> Extracts	34
3.3	Bioassay-guided Fractionation of the <i>V. staeheleinoides</i> Extracts	35
3.3.1	Bioassay-guided Fractionation of P01009A	35
3.3.2	Bioassay-guided Fractionation of P01009B	35
3.4	Targeted Purification of Active Compounds from <i>V. staeheleinoides</i>	36
3.5	Identification and Characterization of Compounds <b>(50)</b> and <b>(51)</b> from <i>V. staeheleinoides</i>	38
3.5.1	Structural Elucidation of 13-Acetoxy-1,4 $\beta$ -epoxy-8 $\alpha$ -(2-methylpropenoyl)-3-oxo-1,5,7(11)-germacatrien-12,6-olide <b>(50)</b>	39
3.5.2	Structural Elucidation of 13-Acetoxy-8 $\alpha$ -(4-acetoxy-3-methyl-2Z-butenoyl)-1,4 $\beta$ -epoxy-3-oxo-1,5,7(11)-germacatrien-12,6-olide <b>(51)</b>	44
3.5.3	Characterization and Biosynthesis of Compounds <b>(50)</b> and <b>(51)</b>	47
3.6	<i>In vitro</i> Antiplasmodial Activity and Cytotoxicity of Compounds <b>(50)</b> and <b>(51)</b>	49
3.7	Conclusion and Research Prospects	52

## CHAPTER 4

### Antiplasmodial Activity of *Oncosiphon piluliferum*

4.1	<i>Oncosiphon piluliferum</i>	53
4.2	<i>In vitro</i> Antiplasmodial Activity of <i>O. piluliferum</i> Extracts	54
4.3	Bioassay-guided Fractionation of the <i>O. piluliferum</i> Dichloromethane Extract	55
4.3.1	Primary Fractionation of P01609A	55
4.3.2	Further Purification of Fraction 7I	55
4.3.3	Further Purification of Fraction 7M	56
4.3.4	Further Purification of Fraction 7O	58
4.4	Targeted Purification of Compounds <b>(59)</b> – <b>(63)</b> from P01609A	59
4.5	Identification and Characterization of Compounds <b>(59)</b> – <b>(63)</b> from <i>O. piluliferum</i>	62
4.5.1	Structure Elucidation of 4,5 $\alpha$ -epoxy-6 $\alpha$ -hydroxy-1(10) <i>E</i> ,11(13)-germacradien-12,8 $\alpha$ -olide <b>(59)</b>	62
4.5.2	Structure Elucidation of 1 $\beta$ ,6 $\alpha$ -dihydroxy-4(15),11(13)-eudesmadien-12,8 $\alpha$ -olide <b>(60)</b>	68
4.5.3	Structure Elucidation of 1 $\beta$ ,6 $\alpha$ -dihydroxy-3,11(13)-eudesmadien-12,8 $\alpha$ -olide <b>(61)</b>	72
4.5.4	Structure Elucidation of 1 $\alpha$ ,6 $\alpha$ -dihydroxy-4 <i>E</i> ,9 <i>Z</i> ,11(13)-germacratrien-12,8 $\alpha$ -olide <b>(62)</b>	75
4.5.5	Structure Elucidation of 1 $\alpha$ ,6 $\alpha$ -dihydroxy-4 <i>E</i> ,10(14),11(13)-germacratrien-12,8 $\alpha$ -olide <b>(63)</b>	80
4.5.6	Characterization of Compounds <b>(59)</b> – <b>(63)</b>	84
4.5.7	Absolute Configurations of Compounds <b>(59)</b> – <b>(63)</b>	85
4.5.7.1	Mosher Esters of Compound <b>(63)</b>	86
4.5.7.2	Mosher's Method	87
4.5.7.3	Application of Mosher's Method – Absolute Stereochemistry of Compound <b>(63)</b>	87
4.5.7.4	Biosynthesis of Compounds <b>(59)</b> – <b>(62)</b>	89
4.6	NaBH <sub>4</sub> Reduction of Compound <b>(63)</b>	91
4.7	<i>In vitro</i> Antiplasmodial Activity and Cytotoxicity of Compounds from <i>O. piluliferum</i>	94
4.8	Conclusion and Research Prospects	96

## CHAPTER 5

### Experimental

5.1	Plant Material	98
5.2.	Extract Preparation	98
5.3	<i>In Vitro</i> Antiplasmodial Activity	99
5.4	Bioassay-guided Fractionation, Targeted Purification and Selected Derivatisations of Active Compounds	101
5.4.1	Bioassay-guided Fractionation of P01009A	101
5.4.2	Bioassay-guided Fractionation of P01009B	102
5.4.3	Targeted Purification of Active Compounds from P01009A	103
5.4.4	Bioassay-guided Fractionation of P01609A	106
5.4.5	Targeted Purification and Selected Derivatisations of Active Compounds from P01069A	111
5.5	Nuclear Magnetic Resonance (NMR) Spectroscopy	118
5.6	Mass Spectrometry	118
5.7	X-ray Crystallography	118
5.8	Optical Rotations	118
5.9	Melting Point Determinations	118
5.10	<i>In Vitro</i> Cytotoxicity Assay	118
	<i>Appendix (A):</i> Crystallographic data for Compound <b>(60)</b>	121
	<i>Appendix (B):</i> Crystallographic data for Compound <b>(62)</b>	129
	<i>Appendix (C):</i> Crystallographic data for Compound <b>(66)</b>	149
	<i>Appendix (D):</i> Crystallographic data for Compound <b>(63)</b>	157